Drug Abuse, Overuse, and Misuse in Dermatology: Telehealth, Refills, and Emerging Therapies

Conclusions

• The presentation argues that many concerns about “drug abuse” in dermatology are really questions of access, supervision, dosing, and who is prescribing rather than misuse alone.
• It concludes that under-treating patients because of fear, ideology, or regulatory overreaction can be as harmful as overprescribing.
• Telehealth and direct-to-consumer models can improve access, but without careful clinician oversight they can also enable inappropriate self-dosing, uncontrolled refills, and poor outcomes.
• GLP-1 agonists appear promising for weight loss and may have dermatologic anti-inflammatory benefits, but they also create risks of dosing errors, counterfeit or compounded products, eating-disorder behaviors, and body dysmorphic cycles.
• The speaker suggests metformin may be an underused, cheaper alternative that shares some mechanistic overlap with GLP-1 therapies and deserves more attention in dermatology.
• For hair loss, oral minoxidil has a growing evidence base and an extended-release formulation may improve safety and adherence while reducing cardiovascular concerns.
• Patients using low-dose oral minoxidil often seek faster results than recommended, reinforcing the need for counseling, titration, and monitoring rather than unsupervised escalation.
• The speaker believes finasteride, dutasteride, and compounded hair-loss regimens are increasingly commodified online, which can weaken dermatologists’ role in treatment supervision.
• For acne and rosacea, newer agents and low-dose minocycline formulations may improve care while reducing some antibiotic harms, but long-term unsupervised antibiotic use remains a major problem.
• The presentation warns that outdated or overly loose refill practices with tetracyclines and steroids can lead to irreversible pigmentation, striae, resistance, and diagnostic masking.
• Sunscreen ingredient “doping” is presented as an example of regulatory loopholes that may outpace patient transparency and safety oversight.
• The talk argues that biologics and JAK inhibitors are generally safe and effective in appropriately selected patients and may be preferable to older systemic immunosuppressants for many inflammatory skin diseases.
• Overall, the conclusion is that dermatology should prioritize the right drug, right dose, right patient, and right supervision, rather than reflexively avoiding modern therapies out of fear of abuse or cost.